Trials / Unknown
UnknownNCT06031480
Anlotinib and TQB2450 in Advanced Hepatocellular Carcinoma After Failure of Prior Immune Checkpoint Inhibitors
Study of Combination Treatment Using Anlotinib and TQB2450 in Patients With Advanced Hepatocellular Carcinoma Who Failed Prior Immune Checkpoint Inhibitor Therapies: a Single Arm, Multicenter Clinical Trial
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 55 (estimated)
- Sponsor
- Shanghai Zhongshan Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This is an multi-center, single arm, exploratory study to evaluate the efficacy and safety of anlitinib combined with TQB2450 in patients with advanced hepatocellular carcinoma （HCC）who failed prior immune checkpoint inhibitor therapies.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Anlotinib and TQB2450 | Anlotinib: 10mg PO, QD, D1-14, Q3W; TQB2450: 1200 mg, IV, D1, Q3W. Anlotinib and TQB2450 will be administered until the disease progression, intolerable toxicity, death, withdrawal of consent. |
Timeline
- Start date
- 2023-10-31
- Primary completion
- 2025-10-31
- Completion
- 2025-12-31
- First posted
- 2023-09-11
- Last updated
- 2023-09-11
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06031480. Inclusion in this directory is not an endorsement.